Aurora Cannabis Q2 revenue beats estimates on international demand
ACB•Aurora Cannabis’ fiscal second-quarter revenue rose 9% year over year to C$86.02 million, beating the C$72.17 million analyst consensus. Adjusted net income was C$3.11 million and declined year over year.
1. Revenue and income
Aurora Cannabis reported fiscal second-quarter revenue of C$86.02 million, up 9% from a year earlier and above the C$72.17 million consensus estimate. Adjusted net income was C$3.11 million, down year over year.
2. Medical sales trends
Record international medical cannabis revenue rose 44% year over year, mainly on higher sales in Germany and Poland driven by increased patient demand. Canadian medical cannabis revenue fell 24%, which the company attributed mainly to changes in the federal reimbursement program effective April 1, 2026. Consumer cannabis revenue dropped as Aurora shifts its focus to medical cannabis and winds down its consumer business.
3. Planned acquisition
Aurora expects its acquisition by Organigram to close in January 2027, pending approvals.
